Demodex mites, tiny organisms that live in the eyelashes, are usually harmless but can lead to conditions such as ocular rosacea, recurring styes, or blepharitis when their population grows unchecked. Symptoms of an infestation include eyelash dandruff, eye dryness, a sensation of foreign particles in the eye, redness, or irritation.
XDEMVY has been developed specifically to treat Demodex blepharitis (DB), marking a significant advancement in the management of this condition. It is the first and only treatment for DB to receive FDA approval. The treatment involves applying one drop of XDEMVY to each eye twice a day, approximately 12 hours apart, for a duration of 6 weeks.
Clinical trials have demonstrated the efficacy of XDEMVY. In two combined studies, 50% of patients experienced a reduction in crusties (collarettes), and 60% of patients had their Demodex mites completely eradicated. Additionally, about 90% of patients reported that the eye drops were neutral to very comfortable to use.
It's crucial for patients to complete the full 6-week treatment course to achieve the best outcomes. Patients using XDEMVY for DB may see a reduction in eyelid redness within this period.
The treatment was evaluated in two pivotal trials involving 833 patients, with 415 receiving XDEMVY. In Trial 1, 44% of patients saw a reduction in collarettes to 2 or less for the upper eyelid, and 68% had their mites completely eradicated by Day 43. In Trial 2, 55% of patients experienced a reduction in collarettes, and 50% had their mites eradicated by the same day.
XDEMVY represents a significant step forward in the treatment of Demodex blepharitis, offering hope to those suffering from this condition.
